Literature DB >> 15196850

Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.

Denis Lane1, Andréanne Cartier, Sylvain L'Espérance, Marceline Côté, Claudine Rancourt, Alain Piché.   

Abstract

OBJECTIVES: In this study, we examine the sensitivity of a panel of ovarian carcinoma cells, which includes four primary ovarian cancer cell samples, and four normal ovarian epithelium samples to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). We also examine the intracellular regulation of TRAIL-mediated apoptosis.
METHODS: The sensitivity to TRAIL was determined by short-term survival assays on seven ovarian carcinoma cell lines, four primary samples of ovarian cancer, and four normal ovarian epithelium samples. We assessed the activation of the apoptotic pathway in TRAIL-resistant and -sensitive tumor cells. The expression of TRAIL receptors was determined by flow cytometry. The protein expression of FADD, XIAP, caspase-8, caspase-3, BAX, and c-FLIP were determined by immunoblot analyses.
RESULTS: We show that ovarian cancer cells display variable sensitivity to TRAIL-induced apoptosis although most cell lines have similar sensitivity to cisplatin. Normal ovarian epithelium samples were mostly sensitive to TRAIL. In sensitive cells, TRAIL induced caspase-8-dependent apoptosis, which subsequently led to activation of caspase-3. Both sensitive and resistant cells expressed caspase-8, caspase-3, FADD, XIAP, and c-FLIP at similar levels. A significant enhancement in cell death was observed in TRAIL-resistant cells when c-FLIP(L) levels were downregulated by RNA interference.
CONCLUSIONS: These data suggest that sensitivity to TRAIL and chemotherapy does not necessarily correlate in human ovarian cancer cells. Cancerous cells isolated from patients with ovarian cancer show variable sensitivity to TRAIL but most normal ovarian epithelial cells are sensitive. In human ovarian cancer cells, c-FLIP(L) may participate to the regulation of the TRAIL signaling cascade.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196850     DOI: 10.1016/j.ygyno.2004.03.029

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  B lymphocytes are resistant to death receptor 5-induced apoptosis.

Authors:  Roslyn N Crowder; Hong Zhao; W Winn Chatham; Tong Zhou; Robert H Carter
Journal:  Clin Immunol       Date:  2011-01-28       Impact factor: 3.969

2.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

3.  Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.

Authors:  Christina Menke; Lianghua Bin; Jacqueline Thorburn; Kian Behbakht; Heide L Ford; Andrew Thorburn
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

4.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 5.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.

Authors:  Silvia von Karstedt; Antonella Montinaro; Henning Walczak
Journal:  Nat Rev Cancer       Date:  2017-05-24       Impact factor: 60.716

6.  Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis.

Authors:  Penny Clarke; Kenneth L Tyler
Journal:  Apoptosis       Date:  2007-01       Impact factor: 4.677

7.  The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  J Ovarian Res       Date:  2010-01-18       Impact factor: 4.234

Review 8.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

Authors:  Andrew Thorburn; Kian Behbakht; Heide Ford
Journal:  Drug Resist Updat       Date:  2008-04-18       Impact factor: 18.500

9.  Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer.

Authors:  Sarah Ouahoud; Philip W Voorneveld; Lukas J A C Hawinkels; James C H Hardwick; Lennart R A van der Burg; Eveline S M de Jonge-Muller; Mark J A Schoonderwoerd; Madelon Paauwe; Thijs de Vos; Sophie de Wit; Gabi W van Pelt; Wilma E Mesker
Journal:  Oncogene       Date:  2020-01-23       Impact factor: 9.867

10.  Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells.

Authors:  Isabelle Matte; Denis Lane; Elodie Côté; Ann-Elise Asselin; Louis-Charles Fortier; Claude Asselin; Alain Piché
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.